Baudax Bio Inc. (BXRX)
Baudax Bio Statistics
Share Statistics
Baudax Bio has 0 shares outstanding. The number of shares has increased by 0% in one year.
| Shares Outstanding | 0 |
| Shares Change (YoY) | 0% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 43.59M |
| Failed to Deliver (FTD) Shares | 13.83K |
| FTD / Avg. Volume | 3.26% |
Short Selling Information
| Short Interest | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Valuation Ratios
The PE ratio is -0.02 and the forward PE ratio is null. Baudax Bio's PEG ratio is 0.
| PE Ratio | -0.02 |
| Forward PE | n/a |
| PS Ratio | 0.83 |
| Forward PS | null |
| PB Ratio | -0.04 |
| P/FCF Ratio | -0.04 |
| PEG Ratio | 0 |
Enterprise Valuation
Baudax Bio has an Enterprise Value (EV) of 2.91M.
| EV / Sales | 2.3 |
| EV / EBITDA | -0.08 |
| EV / EBIT | -0.1 |
| EV / FCF | -0.1 |
Financial Position
The company has a current ratio of 0.3, with a Debt / Equity ratio of -0.29.
| Current Ratio | 0.3 |
| Quick Ratio | 0.3 |
| Debt / Equity | -0.29 |
| Debt / EBITDA | -0.2 |
| Debt / FCF | -0.26 |
| Interest Coverage | -1.7 |
Financial Efficiency
Return on Equity is 242.53% and Return on Invested Capital is 208.74%.
| Return on Equity | 242.53% |
| Return on Assets | -586.07% |
| Return on Invested Capital | 208.74% |
| Revenue Per Employee | $141K |
| Profits Per Employee | $-6.53M |
| Employee Count | 9 |
| Asset Turnover | 0.13 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by 17.65% in the last 52 weeks. The beta is 1.58, so Baudax Bio's price volatility has been higher than the market average.
| Beta | 1.58 |
| 52-Week Price Change | 17.65% |
| 50-Day Moving Average | 0.02 |
| 200-Day Moving Average | 0.27 |
| Relative Strength Index (RSI) | 47.49 |
| Average Volume (20 Days) | 424.85K |
Income Statement
In the last 12 months, Baudax Bio had revenue of 1.27M and earned -58.8M in profits. Earnings per share was -177.3.
| Revenue | 1.27M |
| Gross Profit | -5.74M |
| Operating Income | -35.74M |
| Net Income | -58.8M |
| EBITDA | -35.58M |
| EBIT | -37.73M |
| Earnings Per Share (EPS) | -177.3 |
Balance Sheet
The company has 5.26M in cash and 7.12M in debt, giving a net cash position of -1.86M.
| Cash & Cash Equivalents | 5.26M |
| Total Debt | 7.12M |
| Net Cash | -1.86M |
| Retained Earnings | -190.9M |
| Total Assets | 20.58M |
| Working Capital | -17.71M |
Cash Flow
In the last 12 months, operating cash flow was -27.79M and capital expenditures -20K, giving a free cash flow of -27.81M.
| Operating Cash Flow | -27.79M |
| Capital Expenditures | -20K |
| Free Cash Flow | -27.81M |
| FCF Per Share | -83.87 |
Margins
Gross margin is -452.32%, with operating and profit margins of -2816.63% and -4633.18%.
| Gross Margin | -452.32% |
| Operating Margin | -2816.63% |
| Pretax Margin | -4633.18% |
| Profit Margin | -4633.18% |
| EBITDA Margin | -2803.62% |
| EBIT Margin | -2816.63% |
| FCF Margin | -2191.73% |
Dividends & Yields
BXRX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -5575.44% |
| FCF Yield | -2637.46% |
Analyst Forecast
Currently there are no analyst rating for BXRX.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Stock Splits
The last stock split was on Dec 1, 2022. It was a backward split with a ratio of 1:40.
| Last Split Date | Dec 1, 2022 |
| Split Type | backward |
| Split Ratio | 1:40 |
Scores
| Altman Z-Score | -15.9 |
| Piotroski F-Score | 1 |